IceCure Medical Ltd. (NASDAQ:ICCM) Given Average Recommendation of “Hold” by Analysts

Shares of IceCure Medical Ltd. (NASDAQ:ICCM) have earned a consensus rating of “Hold” from the five research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $2.09.

ICCM has been the topic of several recent research reports. Maxim Group reduced their price target on IceCure Medical from $3.00 to $1.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen raised shares of IceCure Medical from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research report on Tuesday, April 21st. Finally, Alliance Global Partners initiated coverage on shares of IceCure Medical in a research note on Monday, May 4th. They issued a “buy” rating for the company.

Hedge Funds Weigh In On IceCure Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ICCM. Virtu Financial LLC purchased a new stake in shares of IceCure Medical during the fourth quarter worth about $39,000. Concurrent Investment Advisors LLC purchased a new position in IceCure Medical in the fourth quarter valued at about $48,000. Finally, Jane Street Group LLC purchased a new position in IceCure Medical in the fourth quarter valued at about $67,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

IceCure Medical Price Performance

NASDAQ:ICCM opened at $0.23 on Friday. The business’s 50-day moving average is $0.33 and its two-hundred day moving average is $0.54. The firm has a market capitalization of $18.53 million, a PE ratio of -0.95 and a beta of 0.47. IceCure Medical has a 12 month low of $0.22 and a 12 month high of $1.40.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.03). IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%.The company had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $1.34 million. Equities analysts anticipate that IceCure Medical will post -0.15 EPS for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.